featured
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial
JAMA Neurol 2022 Aug 01;79(8)758-767, E Teng, PT Manser, K Pickthorn, F Brunstein, M Blendstrup, S Sanabria Bohorquez, KR Wildsmith, B Toth, M Dolton, V Ramakrishnan, A Bobbala, SAM Sikkes, M Ward, RN Fuji, GA KerchnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.